Episode 19, Part 2: A reluctant prescriber on the aducanumab decision

This week is a special two-part episode focusing on last week’s controversial — some say inflammatory — decision to approve aducanumab, a new Alzheimer’s drug. In these episodes, I talk with two Alzheimer’s experts with vastly different viewpoints on the news. Second up: Jason Karlawish, an Alzheimer’s physician who wrote a First Opinion in May about how he would not prescribe the drug, were it to be approved.